Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.80
Bid: 9.35
Ask: 9.75
Change: 0.20 (2.08%)
Spread: 0.40 (4.278%)
Open: 10.20
High: 10.40
Low: 9.80
Prev. Close: 9.60
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

20 Jun 2014 13:41

RNS Number : 1742K
e-Therapeutics plc
20 June 2014
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

E-Therapeutics plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Invesco Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

19 June 2014

6. Date on which issuer notified:

20 June 2014

7. Threshold(s) that is/are crossed orreached: vi, vii

37%,36%,35%,34%,33% & 32%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

Ordinary 1p Shares

GB00B2823H99

102,724,060

102,724,060

84,524,060

32.01%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

84,524,060

32.01%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Invesco Fund Managers Limited - 81,738,356

Invesco Asset Management Limited - 2,785,704

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Philippa Sadler

15. Contact telephone number:

01491 417 000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAAKEALELEFF
Date   Source Headline
11th Feb 20133:38 pmRNSDirector/PDMR Shareholding
11th Feb 20137:00 amBUSe-Therapeutics to raise £40 million to advance lead cancer drug and exploit network pharmacology platform
8th Jan 20131:07 pmRNSHolding(s) in Company
18th Dec 20127:00 amBUSClinical Trial Update (ETS2101)
14th Nov 20123:30 pmRNSDirector/PDMR Shareholding
8th Nov 20126:01 pmRNSDirector/PDMR Shareholding
26th Oct 201210:25 amRNSDirector/PDMR Shareholding
23rd Oct 20125:23 pmRNSDirector/PDMR Shareholding
22nd Oct 20127:00 amBUSInterim Results for the six months ended 31 July 2012
2nd Oct 20128:57 amRNSDirector/PDMR Shareholding
25th Sep 20124:19 pmRNSDirector/PDMR Shareholding
12th Sep 20127:00 amBUSe-Therapeutics starts second phase I cancer trial of ETS2101
4th Sep 201211:00 amRNSNotice of Interim Results
6th Aug 20122:25 pmRNSAdditional Listing and Directors' Shareholdings
2nd Aug 20123:35 pmRNSAdditional Listing
31st Jul 20121:06 pmRNSResult of AGM
18th Jul 20125:14 pmRNSHolding(s) in Company
6th Jul 20122:08 pmBUSDirector/PDMR Shareholding
29th Jun 20121:03 pmRNSAnnual Financial Report
19th Jun 20127:00 amBUSe-Therapeutics' ETS2101 enters phase I clinical trial in brain cancer
22nd May 20127:03 amBUSe-Therapeutics' Preliminary Results for the Year Ended 31 January 2012
10th May 20127:00 amRNSNotice of Results
4th May 20126:00 pmRNSDirector/PDMR Shareholding
17th Apr 20123:55 pmRNSChange of Registered Office
29th Mar 20127:00 amBUSPhase I clinical trials of cancer drug ETS2101 approved by regulators
14th Mar 20125:59 pmRNSDirector/PDMR Shareholding
27th Feb 20127:00 amBUSPrime Minister Opens e-Therapeutics' Drug Discovery Centre near Oxford
8th Feb 20122:00 pmBUSe-Therapeutics to Present at The 14th Annual BIO CEO & Investor Conference
7th Feb 20128:41 amRNSHolding(s) in Company
6th Feb 20127:00 amBUSDirectorate Change
9th Jan 20122:00 pmBUSe-Therapeutics outlines goals for 2012 and announces presentation at Biotech Showcase Conference
30th Nov 20113:45 pmRNSDirector/PDMR Shareholding
27th Oct 201110:21 amRNSDirector/PDMR Shareholding
19th Oct 20117:00 amRNSInterim Results for the six months to 31 July 2011
26th Sep 20117:00 amRNSPatent for 'Power Behind the Throne'
21st Sep 20119:00 amRNSNotice of Interim Results
12th Sep 20111:06 pmRNSResult of AGM
17th Aug 20114:19 pmRNSDirector/PDMR Shareholding
15th Aug 20112:16 pmRNSDirector/PDMR Shareholding
9th Aug 201112:40 pmRNSDirector/PDMR Shareholding
28th Jul 201110:00 amRNSAnnual Financial Report
28th Jul 20117:30 amRNSDirector/PDMR Shareholding
25th Jul 20117:00 amRNSPreliminary Results and Business Update
29th Jun 20112:38 pmRNSNotice of Results
13th Jun 20117:00 amRNSDirectorate Change
6th Jun 20114:34 pmRNSAdditional Listing
24th May 20116:30 pmRNSDirector/PDMR Shareholding
23rd May 20115:59 pmRNSDirector/PDMR Shareholding
15th Mar 20112:47 pmRNSDirector/PDMR Shareholding
15th Mar 201110:35 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.